HealthcareServices

Global Lung Cancer Diagnostic And Screening Market Report 2026: Emerging Trends and Growth Scenarios

February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the lung cancer diagnostic and screening market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Lung Cancer Diagnostic And Screening Market?

The lung cancer diagnostic and screening market has demonstrated robust expansion over recent years. Its valuation is anticipated to rise from $2.56 billion in 2025 to $2.8 billion in 2026, progressing at a compound annual growth rate (CAGR) of 9.4%. This historical growth can be ascribed to several factors, including the significant prevalence of smoking-related lung cancer, the extensive utilization of chest x-ray and CT imaging, the development of hospital-based diagnostic infrastructure, increasing public awareness regarding early lung cancer detection, and the rise in biopsy-based diagnostic confirmations.

The lung cancer diagnostic and screening market is projected to experience substantial expansion, reaching $4.04 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period stems from several factors, including the wider implementation of national lung cancer screening programs, increased uptake of low-dose CT screening, a rising need for biomarker and blood-based tests, greater healthcare investments in oncology diagnostics, and enhanced accessibility to diagnostic imaging centers. Key trends expected during this period involve the increasing embrace of early lung cancer screening programs, a surge in the utilization of advanced imaging and biomarker tests, a heightened emphasis on screening high-risk populations, the broadening of non-invasive diagnostic techniques, and a growing integration of multimodal diagnostic approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Drivers Are Supporting Technological Adoption In The Lung Cancer Diagnostic And Screening Market?

The expansion of the lung cancer diagnostic and screening market is anticipated to be driven by the rising incidence of lung cancer. Characterized by the uncontrolled multiplication of abnormal cells within lung tissues, lung cancer is a serious illness presenting symptoms like coughing, chest discomfort, and breathing difficulties. These diagnostic and screening procedures, encompassing tests such as incisional biopsy and bronchoscopy, enable the early detection of the condition in individuals affected by lung cancer. For example, data from the American Cancer Society, a US-based government entity, indicated that in January 2023, the United States recorded around 238,340 new instances of lung cancer (comprising 117,550 in men and 120,790 in women). Moreover, a reported 127,070 fatalities resulted from lung cancer (with 67,160 occurring in men and 59,910 in women). Consequently, the increased occurrence of lung cancer is fueling the expansion of the lung cancer diagnostic and screening market.

What Segment Types Are Examined In The Lung Cancer Diagnostic And Screening Market?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

Which Trends Are Influencing The Development Of The Lung Cancer Diagnostic And Screening Market?

Leading companies in the lung cancer diagnostic and screening market are concentrating on developing a blood-based test that utilizes machine learning, such as whole-genome machine learning, to provide accessible and convenient lung cancer screening and gain a competitive advantage in the market. Whole-genome machine learning involves the application of machine learning algorithms to analyze and interpret comprehensive sets of genetic information, encompassing an organism’s entire genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, launched FirstLook Lung, a blood test employing whole-genome machine learning to analyze cell-free DNA fragments, thereby enhancing lung cancer screening with a 99.7% NPV. The test, designed for routine blood work, identifies individuals with potential lung cancer, including early-stage disease. By addressing low LDCT screening uptake, the test aims to improve population health.

Who Are The Prominent Global Companies Shaping The Lung Cancer Diagnostic And Screening Market Landscape?

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Region Is Projected To Lead The Lung Cancer Diagnostic And Screening Market During The Forecast Period?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Lung Cancer Diagnostic And Screening Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2026, By The Business Research Company

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Respiratory Disease Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795